scholarly article | Q13442814 |
P356 | DOI | 10.1007/S12026-016-8812-Z |
P698 | PubMed publication ID | 27406736 |
P50 | author | Mara Taraborelli | Q56479030 |
Laura Andreoli | Q61806166 | ||
Angela Tincani | Q73304219 | ||
Amelia Ruffatti | Q92104506 | ||
Marta Tonello | Q114417398 | ||
Pier Luigi Meroni | Q38544871 | ||
Vittorio Pengo | Q42778559 | ||
P2093 | author name string | Rajesh Kumar | |
Lorenza Maria Argolini | |||
Maria Gerosa | |||
Antonia Calligaro | |||
Entela Nuri | |||
P2860 | cites work | Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus? | Q68556883 |
The efficacy of antimalarials in systemic lupus erythematosus | Q71523954 | ||
Anti-beta 2-glycoprotein I antibodies: a marker of antiphospholipid syndrome? | Q72345769 | ||
Antimalarial agents: closing the gate on Toll-like receptors? | Q79158393 | ||
Antinucleosome antibodies in primary antiphospholipid syndrome: a hint at systemic autoimmunity? | Q80484528 | ||
APS--more systemic disease than SLE | Q81398865 | ||
Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies | Q83389363 | ||
The anticardiolipin syndrome | Q93670719 | ||
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 | ||
Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients | Q33412915 | ||
Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort | Q33871715 | ||
Antiphospholipid Syndrome Clinical Research Task Force report | Q34163321 | ||
Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies | Q35928782 | ||
Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis | Q36747001 | ||
Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers | Q36843689 | ||
Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus | Q37158591 | ||
Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients | Q37803363 | ||
The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus | Q38446538 | ||
Hydroxychloroquine treatment of rheumatoid arthritis | Q39531636 | ||
Clinical course of high-risk patients diagnosed with antiphospholipid syndrome | Q39934417 | ||
Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties. | Q40877489 | ||
The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. | Q40903111 | ||
Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. | Q41109148 | ||
Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events | Q41911950 | ||
Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort | Q41917167 | ||
Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy | Q41919785 | ||
Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (third of three parts) | Q41931569 | ||
On the inhibitory effect of chloroquine on blood platelet aggregation | Q41935192 | ||
Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial | Q41936586 | ||
Inhibition by chloroquine of the class II major histocompatibility complex-restricted presentation of endogenous antigens varies according to the cellular origin of the antigen-presenting cells, the nature of the T-cell epitope, and the responding T | Q41936680 | ||
A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus | Q41942545 | ||
Metabolism of chloroquine and hydroxychloroquine in albino and pigmented rats | Q41942733 | ||
Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids | Q41943371 | ||
Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling | Q41944676 | ||
Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. | Q43417859 | ||
Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients | Q44830352 | ||
Biochemical characterization of ADP-ribose polymer metabolism in SLE. | Q51031046 | ||
Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. | Q53190445 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | hydroxychloroquine | Q421094 |
P304 | page(s) | 17-24 | |
P577 | publication date | 2016-07-13 | |
P1433 | published in | Immunologic Research | Q15754981 |
P1476 | title | Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome | |
P478 | volume | 65 |
Q96304889 | An update on the management of antiphospholipid syndrome |
Q94940476 | Antiphospholipid Syndrome |
Q58602902 | Antiphospholipid syndrome: state of the art on clinical practice guidelines |
Q55479438 | Arterial/venous thrombosis, fetal loss and stillbirth in pregnant women with systemic lupus erythematosus versus primary and secondary antiphospholipid syndrome: a systematic review and meta-analysis. |
Q64101902 | Cerebellar Atrophy and Neurocognitive Disorder as Primary Presentation of Antiphospholipid Syndrome in a Young Male |
Q47982275 | Diagnosis and management of the antiphospholipid syndrome |
Q98181529 | Management of anticoagulant-refractory thrombotic antiphospholipid syndrome |
Q89603158 | Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology |
Q89986376 | Pediatric APS: State of the Art |
Q88203849 | Role of environmental factors in autoimmunity: pearls from the 10th international Congress on autoimmunity, Leipzig, Germany 2016 |
Q88399624 | The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository |
Q94672281 | The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis? |
Q93020058 | The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS |
Q88930539 | Thrombosis and Anti-phospholipid Syndrome: a 5-Year Update on Treatment |
Q33443797 | Thrombosis and antiphospholipid antibody syndrome during acute Q fever: A cross-sectional study |
Q64086736 | Type I Interferon Signature in Primary Antiphospholipid Syndrome: Clinical and Laboratory Associations |
Q52654857 | Update on Antiphospholipid Syndrome: Ten Topics in 2017. |
Search more.